Faculty Disclosures

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, course directors, planners, moderators, faculty, and all others in control of the educational content of the continuing education activity must disclose all financial relationships with ineligible companies that they may have had within the past 24 months. If an individual refuses to disclose financial relationships, they will be disqualified from being a part of the planning and implementation of the activity. Owners and/or employees of an ineligible company with business lines or products relating to the content of the activity will not be permitted to participate in the planning or execution of any accredited program. All listed relevant financial relationships with ineligible companies for individuals in control of content have been mitigated.

Nature of Relevant Financial Name Role in Activity Ineligible Company Relationship Faculty, Planning  Bristol Myers Squibb, Takeda Pharmaceutical Company, Boland  Advisory Board Committee Ltd.

 AbbVie, Inc. Bristol Myers Squibb, Janssen Faculty, Planning  Advisor, Speaker Collins Pharmaceuticals, Takeda Pharmaceutical Company, Ltd. Committee  Independent Contractor  MedscapeTV

Faculty, Planning Coyle  AbbVie, Inc.  Speaker’s Bureau Committee

 CRC Press, UpToDate  Consultant DiBaise Faculty  Zealand Pharmaceuticals  Advisor

 AbbVie, Inc., Bristol Myers Squibb, Lilly, Janssen Faculty, Planning Biosciences, Pfizer, Inc., Takeda Pharmaceutical  Consultant Dulai Committee Company, Ltd.  Advisor  Digbi Health Faculty, Planning Ferrari  None  N/A Committee Faculty, Planning  Takeda Pharmaceuticals USA, Inc.  Speaker Konijeti Committee  Pfizer, Inc., ProciseDx  Advisor Faculty, Planning Matro  None  N/A Committee

Moein Jahromi Peer Reviewer  None  N/A

 AbbVie, Inc., Abivax, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene, Genentech, Gilead Sciences, Glaxo Smith Kline, Janssen, Lilly, Pfizer, Prometheus Biosciences, Seres Therapeutics, Shire, Takeda Pharmaceutical Company, Ltd., Theravance Biopharma  AbbVie, Inc., Abivax, Admirx, Alfasigma, Alimentiv (previously Robarts Clinical Trials, owned by Alimentiv Health Trust), Alivio Therapeutics, Allakos, Allergan, Amgen, Applied Molecular Transport, Arena Pharmaceuticals, Avexegen Therapeutics, Bausch Health (Salix), BeiGene, Bellatrix Pharmaceuticals, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Meyer Squibb, Celgene, Celltrion, Cellularity, Conatus, Cosmo Pharmaceuticals, Escalier Biosciences, Ferring, Forbion, Equillium, Genentech/Roche, Gilead Sciences, Glenmark Pharmaceuticals, Gossamer Bio, Immunic (Vital Therapies), Incyte, Index Pharmaceuticals, Intact  Research Faculty, Planning Therapeutics, Janssen, Kyowa Kirin Pharmaceutical Sandborn  Consultant Committee Research, Kyverna Therapeutics, Landos Biopharma,  Stock, Stock Options Lilly, Miraca Life Sciences, Nivalis Therapeutics, Novartis, Nutrition Science Partners, Oppilan Pharma, Otsuka, Pandion Therapeutics, Paul Hastings, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonists Therapeutics, Provention Bio, Reistone Biopharma, Ritter Pharmaceuticals, Seres Therapeutics, Shanghai Pharma Biotherapeutics, Shire, Shoreline Biosciences, Sienna Biopharmaceuticals, Sigmoid Biotechnologies, Sterna Biologicals, Sublimity Therapeutics, Surrozen, Takeda, Theravance Biopharma, Thetis Pharmaceuticals, Tigenix, Tillotts Pharma, UCB Pharma, Vendata Biosciences, Ventyx Biosciences, Vimalan Biosciences, Vivelix Pharmaceuticals, Vivreon Biosciences, Zealand Pharma  Allakos, BeiGene, Gossamer Bio, Oppilan Pharma, Prometheus Biosciences, Prometheus Laboratories, Progenity, Shoreline Biosciences, Ventyx Biosciences, Vimalan Biosciences, Vivreon Biosciences  Arena Pharmaceuticals, AstraZeneca LP, Boehringer‐  Consultant Sands Faculty Ingelheim, Bristol Myers‐Squibb, Celltrion Healthcare Co.  Consultant, Advisory Board Ltd., Galapagos, Index Pharmaceuticals, Kaleido, Target  Consultant, Speaker

New Advances in Inflammatory Bowel Disease September 11, 2021 ● Live Streaming Virtual Event

Pharmasolutions, AbbVie, Alimentiv, Amgen, Bacainn Therapeutics, Boston Pharmaceuticals, Calibr, ClostraBio, Evommune, Glaxo SmithKline, F.Hoffmann‐La Roche AG, Innovation Pharmaceuticals, Inotrem, Ironwood Pharmaceuticals, Inc., Kallyope, MiroBio, Otsuka, Q32 Bio, Redhill Biopharma, Lt., Shire, Surrozen, Theravance Biopharma R&D, Inc., USWM Enterprises  Abivax, GossamerBio, Janssen, Johnson & Johnson, Lilly, Morphic Therapeutic, Pfizer, Prometheus Bioscience, Vivante Health, Ventyx Biosciences, Genentech, Inc., Immunic AG, Oppilan Pharma, Ltd., OSE Immunotherapeutics, Prometheus Laboratories  Takeda Faculty, Planning  AbbVie, Inc., Janssen Biosciences  Research Funding Singh Committee  Pfizer, Inc.  Advisor

Sklow Faculty  None  N/A

Faculty, Planning Worsey  None  N/A Committee CE approval, all final CME Committee decision‐making on  None  N/A activities Scripps Plan, manage, implement, Conference  None  N/A and reconcile CE activities Services & CME

Glossary of Terms

Ineligible Company An ineligible company is any entity whose primary business is producing, marketing, selling, re‐selling, or distributing healthcare products used by or on patients. For specific examples of ineligible companies visit www.accme.org/standards.

Financial Relationships Financial relationships include employee, researcher, consultant, advisor, speaker, independent contractor, research funding, royalties or patent beneficiary, executive role, and ownership interest. Individual stocks and stock options should be disclosed.

New Advances in Inflammatory Bowel Disease September 11, 2021 ● Live Streaming Virtual Event